BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
A major push to sharpen the future of cancer treatment is underway
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
The campaign builds on the three-year partnership unveiled earlier this season
The license is valid for five years, effective from April 9, 2026
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
Subscribe To Our Newsletter & Stay Updated
